Diane Joseph-McCarthy, PhD
Professor of the Practice
Boston University College of Engineering
Biomedical Engineering

PhD, Massachusetts Institute of Technology

Diane Joseph-McCarthy is the Executive Director of the new Bioengineering Technology & Entrepreneurship Center (BTEC) at Boston University. She is a senior life science executive with over 20 years of drug discovery, development, and leadership experience in the pharmaceutical and biotechnology sector. Most recently, she was the Senior Vice President of Discovery & Early Development at EnBiotix, a BU spinout company focused on bioengineering novel antibacterials. Before joining EnBiotix, she was an Associate Director in the Infection iMED at AstraZeneca, where she led an innovative group of scientists as well as a global team in Predictive Science. Prior to that she was at Wyeth where she held positions of increasing responsibility. She has been actively involved in the discovery of several compounds that have reached clinical trials. Dr. Joseph-McCarthy received her BA from BU, her PhD from MIT, and was a postdoctoral fellow at Harvard University and Harvard Medical School. She has more than 70 publications/patents and has given numerous invited talks. She also has served as a member of the National Academy of Sciences Polio Antiviral Advisory Committee.

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Van Egeren D, Stoddard M, White LF, Hochberg NS, Rogers MS, Zetter B, Joseph-McCarthy D, Chakravarty A. Vaccines Alone Cannot Slow the Evolution of SARS-CoV-2. Vaccines (Basel). 2023 Apr 16; 11(4).View Related Profiles. PMID: 37112765; PMCID: PMC10143044; DOI: 10.3390/vaccines11040853;
  2. Walker KC, Shwarts M, Demidikin S, Chakravarty A, Joseph-McCarthy D. Machine learning for the identification of respiratory viral attachment machinery from sequences data. PLoS One. 2023; 18(3):e0281642. PMID: 36862685; PMCID: PMC9980812; DOI: 10.1371/journal.pone.0281642;
  3. Van Egeren D, Stoddard M, Malakar A, Ghosh D, Acharya A, Mainuddin S, Majumdar B, Luo D, Nolan RP, Joseph-McCarthy D, White LF, Hochberg NS, Basu S, Chakravarty A. No magic bullet: Limiting in-school transmission in the face of variable SARS-CoV-2 viral loads. Front Public Health. 2022; 10:941773.View Related Profiles. PMID: 36530725; PMCID: PMC9751474; DOI: 10.3389/fpubh.2022.941773;
  4. Van Egeren D, Stoddard M, Novokhodko A, Rogers MS, Joseph-McCarthy D, Zetter B, Chakravarty A. Rapid relaxation of pandemic restrictions after vaccine rollout favors growth of SARS-CoV-2 variants: A model-based analysis. PLoS One. 2021; 16(11):e0258997. PMID: 34818335; PMCID: PMC8612578; DOI: 10.1371/journal.pone.0258997;
  5. Van Egeren D, Novokhodko A, Stoddard M, Tran U, Zetter B, Rogers MS, Joseph-McCarthy D, Chakravarty A. Controlling long-term SARS-CoV-2 infections can slow viral evolution and reduce the risk of treatment failure. Sci Rep. 2021 11 19; 11(1):22630. PMID: 34799659; PMCID: PMC8604936; DOI: 10.1038/s41598-021-02148-8;
  6. Van Egeren D, Novokhodko A, Stoddard M, Tran U, Zetter B, Rogers M, Pentelute BL, Carlson JM, Hixon M, Joseph-McCarthy D, Chakravarty A. Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein. PLoS One. 2021; 16(4):e0250780. PMID: 33909660; PMCID: PMC8081162; DOI: 10.1371/journal.pone.0250780;
  7. Basu S, Hochberg NS, Senior BA, Joseph-McCarthy D, Chakravarty A. Computational projection of Virion transmission rates to the lower airway from the initial SARS-COV-2 infection at the nasopharynx. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2021; 34:A8-A9. View Publication
  8. Van Egeren D, Novokhodko A, Stoddard M, Tran U, Zetter B, Rogers M, ... Chakravarty A. Risk of evolutionary escape from neutralizing antibodies targeting SARS-CoV-2 spike protein. medRxiv. 2020. View Publication
  9. Lao Y, Joseph-Mccarthy D, Chakravarty A, Balivada PA, Ato P, Ka NK, Basu S. Identifying the optimal parameters for sprayed and inhaled drug particulates for intranasal targeting of SARS-CoV-2 infection sites. 2020.
  10. Koeva M, Gutu AD, Hebert W, Wager JD, Yonker LM, O'Toole GA, Ausubel FM, Moskowitz SM, Joseph-McCarthy D. An Antipersister Strategy for Treatment of Chronic Pseudomonas aeruginosa Infections. Antimicrob Agents Chemother. 2017 12; 61(12). PMID: 28923873; PMCID: PMC5700368; DOI: 10.1128/AAC.00987-17;
Showing 10 of 86 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 86 publications over 30 distinct years, with a maximum of 10 publications in 2005 and 2007


2016 Boston University: Boston University Chemistry Convocation Distinguished Alumni Speaker
2016-2017 Gates Foundation: Grand Challenges Explorations Award, Integrated Systems Biology for Phage/Microbiome Modeling
2015-2017 Massachusetts Life Science Center: Cooperative Research Matching Grant, EBX-001: Eradicating Persistent P. Aeruginosa Infections in CF
2005 Wyeth Research: Wyeth Above and Beyond Award
2004 Wyeth Research: Wyeth Research Team of the Year Award
2004 Wyeth Research: Wyeth Chemical Screening Sciences Publication Award
Contact for Mentoring:

44 Cummington St
Boston MA 02215
Google Map

Joseph-McCarthy's Networks
Click the "See All" links for more information and interactive visualizations
Media Mentions
Similar People
Same Department